Client News

Mainz Biomed Announces Stock Split

Formycon Reports Nine-Month Results for 2024 and Continues Growth Trajectory with Further Operational Success

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

Pentixapharm Holding AG: First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab

Formycon Invites to Earnings Call on the Nine-Month Results 2024 and Announces Participation in International Investor Conferences

Formycon Receives Positive CHMP Opinion for FYB203 (Aflibercept), a Biosimilar Candidate to Eylea® under the Tradenames AHZANTIVE® and Baiama®

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Abivax Presents Third Quarter 2024 Key Financial Information